BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 10 2025
0mins
Source: Globenewswire
eXoZymes Launches BioClick Initiative: eXoZymes Inc. has introduced BioClick, an innovative project aimed at enhancing enzyme engineering for advanced chemical reactions, supported by a $300K NIH grant. This initiative focuses on group transfer reactions and aims to revolutionize the creation of medicines and nutraceuticals.
Advancements in Enzyme Engineering: The BioClick approach incorporates artificial intelligence and high-throughput screening capabilities, allowing rapid testing of enzyme variations. This technology is expected to significantly reduce the time and cost of developing new or improved drugs, potentially unlocking new therapeutic possibilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
